Induction of Complete Haematological Remission After Monotherapy with AntLCD20 Monoclonal Antibody (RITUXIMAB) in a Patient with Alkylating Agent Resistant Waldenstrom's Macroglobulinaemia

Leukemia and Lymphoma

Volumn 36, Issue 42006, 1999, Pages 203-206

  Weide, Rudolf ^a   Heymanns, Jochen ^a   Köppler, Hubert ^a  

^a Haematology/Oncology Group Practice   (Germany)

Author keywords

Rituximab; Therapy; Waldenstrom's Macroglobulinaemia

Indexed keywords

ALKYLATING AGENT; BENDAMUSTINE; CHLORAMBUCIL; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; MITOXANTRONE; PREDNISONE; RITUXIMAB;

AGED; ARTICLE; BLASTOMYCOSIS; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CASE REPORT; DRUG RESISTANCE; HUMAN; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; REMISSION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; WALDENSTROEM MACROGLOBULINEMIA;

AGED; ALKYLATING AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; DRUG RESISTANCE; HUMANS; MALE; WALDENSTROM MACROGLOBULINEMIA;

EID: 0033455590     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428199909145966     Document Type: Article

References (10)

1. MacKenzie M. R., Fudenberg H. H. Macroglobu-linemia An analysis of forty patients. Blood 1972; 39: 874 – 889
2. Kyle R. A., Garton J. P. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc 1987; 62: 719 – 731
3. Kucharska-Pulczynska M., Ellegaard J., Hokland P. Analysis of leucocyte differentiation antigens in blood and marrow from patients with Waldenstrom's macro-globulinemia. Br J Haematol 1987; 65: 395 – 399
4. Dimopoulos M. A., Alexanian R. Waldenstrom's macroglobulinemia. Blood 1994; 83: 1452 – 1459
5. Obrien S., Kantarjian H. M., Keating M. J. Purine analogues in chronic lymphocytic leukemia and Waldenstrom's macroglobulinemia. Ann Oncol 1996; 7 (suppl 6) 27 – 33
6. Maloney D. G., Liles T. M., Czenvinski D. K., Waldichuk C., Rosenberg J., Grillo-Lopez A., Levy R. Phase I clinical trial using escalating single-dose infusion of chi-meric anti-CD20 monoclonal antibody (IDEC-c2b8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457 – 2466
7. Reff M. E., Carner K., Chambers K. S., Chinn P. C., Leonard J. E., Raab R., Newman R. A., Hanna N., Anderson D. R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435 – 445
8. McLaughlin P., Cabanillas F., Grillo-Lopez A. J., Link B. K., Levy R., Czuczman M., Heyman M. R., Williams M., Jain V., Bence-Bruckler I., Ho A. D., Lister J., Rosenberg J., Dallaire B. K., Shen D. IDEC-C2B8 anti-CDZO antibody Final report on a phase III pivotal trial in patients with relapsed low grade or follicular lymphoma. Blood 1996; 88: 90a, (abstr. suppl 1).
9. Coiffier B., Haioun C., Ketterer N., Engert A., Tilly H., Ma D., Johnson P., Lister A., Feuring-Buske M., Radford J. A., Capdeville R., Diehl V., Reyes F. Rituximab (Anti CD 20 monoclonal Antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter Phase II study. Blood 1998; 92: 1927 – 1932
10. Byrd J. C., White C. A., Link B., Thomas S., Valasquez W. S., Rosenberg J., Grillo-Lopez A. J. Rituximab therapy in previously treated Waldenström's macroglobuline-mia: Preliminary evidence of activity. Blood 1998; 92: 433a, (abstr. suppl 1).